Which Biology Marker Can be a Predictor for Higher Syntax Score?

Linda Lison, Irawan Yusuf, Bambang Sutrisna, Peter Kabo, Teguh Santoso, Ferry Sandra


BACKGROUND: Syntax score is a lesion-based angiographic scoring system, originally devised to grade the anatomic complexity of coronary artery disease (CAD) and thereby facilitate consensus in the study of a diagnostic angiogram between surgeons and interventional cardiologists. Suitable biology marker to predict the severity of CAD and to have a treatment decision for revascularization by percutaneous coronary intervention (PCI) or bypass surgery, is still unknown. Which biology marker can be a predictor for higher Syntax score remains unknown as well.

METHODS: Severity of 105 patients who underwent coronary angiography, were evaluated with Syntax score. Laboratory tests were conducted for routine blood test, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), high-sensitivity C-reactive protein (hs-CRP), total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, kidney function, creatinine and hemoglobin A1c (HbA1c).

RESULTS: Ureum had significant correlation with Syntax score, p=0.016 and 95% confidence interval (CI)=0.05-0.55. Result of logistic regression analysis showed that HDL and haematocrit had significant correlation with Syntax score, with cut off point 34 (p=0.02, p=0.0033, respectively). Based on multi-variate analysis, Syntax score 34 = 16 (HDL ≤40 + Ureum ≥23) + 10 (Neutrophil/Lymphocyte ≥3.789) +10 (HbA1c ≥7 ) + 13 ( monocyte ≥9%).

CONCLUSION: HDL cholesterol, ureum, neutrophil-lymphocyte ratio, HbA1c and monocyte altogether can predict the higher Syntax score.

KEYWORDS: syntax, neutrophil, lymphocyte, HDL, cholesterol, ureum, HbA1c, monocyte

Full Text:



Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008; 54: 24-38, CrossRef.

Epstein FH, Rose R. Atherosclerosis - An Inflammatory Disease. N Eng J Med. 1999; 340: 115-26, CrossRef.

Avanzas P, Arroyo-Espliguero R, Cosín-Sales J, Aldama G, Pizzi C, Quiles J, et al. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart. 2004; 90: 847-52, CrossRef.

Ong AT, Serruys PW, Mohr FW, Morice MC, Kappetein AP, Holmes DR Jr, et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am Heart J. 2006; 151: 1194-204, CrossRef.

Garg S, Sarno G, Garcia-Garcia HM, Girasis C, Wykrzykowska J, Dawkins KD, et al. A new tool for the risk stratification of patients with complex coronary artery disease: the Clinical SYNTAX Score. Circ Cardiovasc Interv. 2010; 3: 317-26, CrossRef.

Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009; 360: 961-72, CrossRef.

Girasis C, Garg S, Räber L, Sarno G, Morel MA, Garcia-Garcia HM, et al. SYNTAX score and clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoingpercutaneous coronary interventions: a substudy of SIRolimuseluting stent compared with pacliTAXel-eluting stent for coronary revascularization (SIRTAX) trial. Eur Heart J. 2011; 32: 3115-27, CrossRef.

Yadav M1, Palmerini T, Caixeta A, Madhavan MV, Sanidas E, Kirtane AJ, et al. Prediction of coronary risk by SYNTAX and derived scores: synergy between percutaneous coronary intervention with taxus and cardiac surgery. J Am Coll Cardiol. 2013; 62: 1219-30, CrossRef.

Capodanno D, Capranzano P, Di Salvo ME, Caggegi A, Tomasello D, Cincotta G, et al. Usefulness of SYNTAX score to select patients with left main coronary artery disease to be treated with coronary artery bypass graft. JACC Cardiovasc Interv. 2009; 2: 731-8, CrossRef.

Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2006; 97: 993-6, CrossRef.

Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler Thromb Vasc Biol. 2005; 25: 658-70, CrossRef.

Sahin S, Sarikaya S, Akyol L, Altunkas F, Karaman K. Evaluation of neutrophil to lymphocyte ratio as an indicator of presence of coronary artery disease in diabetic patients. Natl J Med Res. 2013; 3: 300-3, article.

Zazula AD, Précoma-Neto D, Gomes AM, Kruklis H, Barbieri GF, Forte RY, et al. An assessment of neutrophils/lymphocytes ratio in patients suspected of acute coronary syndrome. Arq Bras Cardiol. 2008; 90: 31-6, PMID.

Poludasu S, Cavusoglu E, Khan W, Marmur JD. Neutrophil to lymphocyte ratio as a predictor of long-term mortality in African Americans undergoing percutaneous coronary intervention. Clin Cardiol. 2009; 32: E6-10, CrossRef.

Shen XH, Chen Q, Shi Y, Li HW. Association of neutrophil/ lymphocyte ratio with long-term mortality after ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Chin Med J. 2010; 123: 3438-43, PMID.

Arbel Y, Finkelstein A, Halkin A, Birati EY, Revivo M, Zuzut M, et al. Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis. 2012; 225: 456-60, CrossRef.

Chen J, Chen MH, Li S, Guo YL, Zhu CG, Xu RX, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting the severity of coronary artery disease: A Gensini score assessment. J Atheroscler Thromb. 2014; 21: 1271-82, CrossRef.

Jurewitz DL, Pessegueiro A, Zimmer R, Bhatia R, Tobis J, Lee MS. Preprocedural white blood cell count as a predictor of death and major adverse cardiac events in patients undergoing percutaneous coronary intervention with drug-eluting stents. J Invasive Cardiol. 2009; 21: 202-6, PMID.

Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005; 45: 1638-43, CrossRef.

Akpek M, Kaya MG, Lam YY, Sahin O, Elcik D, Celik T, et al. Relation of neutrophil/lymphocyte ratio to coronary flow to inhospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012; 110: 621-7, CrossRef.

Arbel Y, Finkelstein A, Halkin A, Birati EY, Revivo M, Zuzut M, et al. Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis. 2012; 225: 456-60, CrossRef.

Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med. 1993; 178: 449-60, CrossRef.

Springer TA, Cybulsky MI. Traffic signals on endothelium for leukocytes in health, inflammation, and atherosclerosis. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven; 1996. p.511-38, NLMID.

Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013; 381: 639-50, CrossRef.

DOI: https://doi.org/10.18585/inabj.v6i2.37

Copyright (c) 2014 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Indexed by:






The Prodia Education and Research Institute